The commercial license agreement follows a research collaboration of undisclosed value launched in June 2014 by Genmab and Gilead Sciences. Gilead agreed to use and evaluate DuoBody as well as the HexaBody™ tech platform. Genmab said the agreement is not expected to have a material effect on its 2016 financial guidance. The company has projected operating income of DKK 25 million to 75 million (about $3.8 million to $11.3 million), on revenues of between DKK 825 million and 875 million (about $124 million and $131.5 million). The licensing deal was the second collaboration announced today by Gilead. The biotech giant is partnering with Polyphor to discover and develop macrocycle drugs against unspecified "challenging biological" targets to be selected by Gilead.